<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397731</url>
  </required_header>
  <id_info>
    <org_study_id>2482CESC</org_study_id>
    <nct_id>NCT04397731</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Role of Eus-fnb in the Diagnosis of Autoimmune Pancreatitis</brief_title>
  <acronym>BIO_AIP</acronym>
  <official_title>Role of Endoscopic Ultrasound-guided Fine-needle Biopsy in the Diagnosis of Autoimmune Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the reported histological procurement yield of the end-cutting needles, the&#xD;
      investigators supposed that the use of EUS-FNB in probable AIP patients, generally aimed only&#xD;
      to rule-out malignancy, could provide histological tissue samples useful in enhancing the&#xD;
      diagnostic level reached without histology, or defining the type of AIP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to evaluate the capability of EUS-FNB to enhance diagnostic levels of AIP,&#xD;
      that means to obtain definitive diagnosis of type 1 and type 2 AIP. Secondary aims are to&#xD;
      evaluate: Safety of EUS-FNB in this setting of patients; the possibility to obtain a&#xD;
      definitive diagnosis in focal/segmental form of AIP (that are the most clinically relevant&#xD;
      because of the mimicking of cancer); diagnostic yield of EUS-FNB in this patient population;&#xD;
      the rate of pancreatic neoplasms mimicking AIP.&#xD;
&#xD;
      Consecutive patients ≥ 18 years old, with suspected focal or diffuse AIP, according to ICDC&#xD;
      (probable type 1 AIP; probable type 2 AIP; NOS-AIP) with written consent to participate in&#xD;
      the study will be enrolled.&#xD;
&#xD;
      Exclusion criteria include: previous diagnosis of AIP; definitive type 1 AIP; steroid&#xD;
      administration within 3 months before the EUS-FNB; coagulation disorders; pregnancy and&#xD;
      lactation; unability to give informed consent .&#xD;
&#xD;
      The histopathology of the preparations will be evaluated, according to the ICDC, including&#xD;
      the LPSP findings and the IDCP findings and recording the absence or presence of specific&#xD;
      criteria: Periductal lymphoplasmacytic infiltrate without GELs, Storiform fibrosis,&#xD;
      Obliterative phlebitis &gt;10 IgG4-positive cells per HPF; GEL of duct wall; Granulocytic and&#xD;
      lympho- plasmacytic acinar infiltrate.&#xD;
&#xD;
      According to the current clinical practice, when the diagnosis of AIP is confirmed (and&#xD;
      malignancy is ruled-out) patient will be treated with the standard therapy for AIP. Patients&#xD;
      will be followed for 12 months, in order to exclude misdiagnosed malignancy, and to evaluate&#xD;
      the clinical course of the disease (response to steroid therapy, relapses, changes in imaging&#xD;
      findings or surgical pathology in resected patients).&#xD;
&#xD;
      The final diagnosis of AIP will be confirmed on surgical pathology (in resected patients) or&#xD;
      when a compatible clinical course is observed during a follow-up of at least 1 year&#xD;
      (significant improvement on imaging after steroid therapy, no appearance of metastasis or&#xD;
      sign of infiltration).&#xD;
&#xD;
      The number of cases where EUS-FNB histology improves the diagnostic level will be summarized&#xD;
      using absolute and relative frequencies. The 95% confidence interval of this proportion will&#xD;
      also be computed. The number of adverse events, the number of cases where histological&#xD;
      finding diagnostic of AIP are observed in focal/segmental form and the number of pancreatic&#xD;
      neoplasm will be summarized using absolute and relative frequencies. Sensitivity,&#xD;
      specificity, positive likelihood ratio (LR+), negative likelihood Ratio (LR-) and the ROC&#xD;
      curve will be used to analyze the capability of EUS-FNB to obtain a definitive diagnosis of&#xD;
      type 1 and 2 AIP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>The primary aim is to evaluate the capability of EUS-FNB to enhance diagnostic levels of AIP, that means to obtain definitive diagnosis of type 1 and type 2 AIP.</measure>
    <time_frame>2 years</time_frame>
    <description>For the primary aim, the endpoint is the percentage of cases where EUS-FNB histology improve the diagnostic level:&#xD;
from a probable AIP 1 to definitive AIP 1 (i.e., percentage of type 1 Level 1 H);&#xD;
from a probable AIP 2 to definitive AIP 2 (i.e., percentage of type 2 Level 1 H);&#xD;
from an AIP-NOS to AIP 1 or 2 (i.e., percentage of type 1 and 2, Level 1 H or Level 2 H).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of EUS-FNB in AIP patients: percentage of adverse events observed</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of adverse events observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The possibility to obtain a definitive diagnosis in focal/segmental form of AIP (that are the most clinically relevant because of the mimicking of cancer).</measure>
    <time_frame>2 years</time_frame>
    <description>The Percentage of cases where histological finding diagnostic of AIP (Level 1 and Level 2) are observed in focal/segmental form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield of EUS-FNB in this patient population.</measure>
    <time_frame>2 years</time_frame>
    <description>The sensitivity, specificity, PPV, NPV, and accuracy calculated in comparison with the final diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of pancreatic neoplasms mimicking AIP</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of pancreatic neoplasm in the study population</description>
  </secondary_outcome>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Autoimmune Pancreatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected AIP who need histological sampling for diagnosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients ≥ 18 years old;&#xD;
&#xD;
          -  Suspected focal or diffuse AIP, according to ICDC:&#xD;
&#xD;
        Probable type 1 AIP Probable type 2 AIP NOS-AIP&#xD;
&#xD;
        • provision of written consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous diagnosis of AIP&#xD;
&#xD;
          -  Definitive type 1 AIP&#xD;
&#xD;
          -  Steroid administration within 3 months before the EUS-FNB&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Francesco Crinò</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Integrata Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Francesco Crinò</last_name>
    <phone>+390458126169</phone>
    <email>stefanofrancesco.crino@aovr.veneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Francesco Crinò, MD</last_name>
      <phone>00390458126169</phone>
      <email>stefanofrancesco.crino@aovr.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tsukasa Ikeura</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsukasa Ikeura, MD</last_name>
      <email>ikeurat@hirakata.kmu.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Integrata Verona</investigator_affiliation>
    <investigator_full_name>Stefano Francesco Crinò, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ICDC criteria</keyword>
  <keyword>AIP</keyword>
  <keyword>HISTOLOGY IN AIP</keyword>
  <keyword>EUS-FNB</keyword>
  <keyword>Endoscopic fine needle biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Autoimmune Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

